De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.
Umar WazirKefah MokbelPublished in: European journal of breast health (2021)
Breast cancer treatment has seen many advances in recent decades, lessening the morbidity to patients, while improving outcomes. Central to these gains has been the introduction of breast conserving surgery and neoadjuvant systemic therapy (NST). There is a considerable interest in further de-escalation of the treatment of breast cancer, which is being studied in several ongoing randomised trials. We aimed to appraise the current literature regarding the various aspects of de-escalation of surgical treatment of breast cancer after NST, and attempt to prognosticate the future course of breast oncotherapy.
Keyphrases
- open label
- minimally invasive
- end stage renal disease
- rectal cancer
- coronary artery bypass
- lymph node
- chronic kidney disease
- ejection fraction
- locally advanced
- randomized controlled trial
- squamous cell carcinoma
- type diabetes
- metabolic syndrome
- peritoneal dialysis
- prognostic factors
- radiation therapy
- study protocol
- mesenchymal stem cells
- neoadjuvant chemotherapy
- combination therapy
- weight loss
- percutaneous coronary intervention
- smoking cessation